Today, the standard treatment for patients with clinical Stage I non-seminomatous testicular germ cell tumors (NSTGCT) following orchidectomy is either primary retroperitoneal lymph node dissection (RPLND) or close surveillance with cisplatin-based polychemotherapy in case of a relapse. Both treatme
Results of a policy of surveillance in stage I testicular seminoma
β Scribed by Padraig R. Warde; Mary K. Gospodarowicz; Phyllis J. Goodman; Jeremy F. Sturgeon; Michael A. Jewett; Charles N. Catton; Hugh Richmond; Gillian M. Thomas; William Duncan; Alastair J. Munro
- Publisher
- Elsevier Science
- Year
- 1993
- Tongue
- English
- Weight
- 604 KB
- Volume
- 27
- Category
- Article
- ISSN
- 0360-3016
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Background and Objectives: Testicular seminoma is a very radiosensitive and curable cancer, with survival rates following radiation therapy within the range of 90-98% without apparent severe side effects. However, long-term survival following exposure to moderate-dose radiation therapy can result in
II seminoma (based on the Royal Marsden staging system) received paraaortic and pelvic lymph node radiation after radical orchiectomy. Patient records were 1 Department of Radiation Oncology, M. D. Anreviewed and patients surveyed to determine the tests ordered for posttreatment derson Cancer Center